Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MAP2K1



This biomarker is also known as:
  • mitogen-activated protein kinase kinase 1,
  • MEK1,
  • MEK 1,
  • MAPKK1,
  • protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1),
  • MKK1,
  • MAP kinase kinase 1,
  • ERK activator kinase 1,
  • EC,
  • dual specificity mitogen-activated protein kinase kinase 1,
  • MAPK/ERK kinase 1,
  • PRKMK1,
  • MAPKK 1,

View in BioMuta


MAP2K1, or mitogen-activated protein kinase kinase 1, is a dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. MAP2K1 is located upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. MAP2K1 is thought to be involved in binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors, as well as cellular processes such as proliferation, differentiation, transcription regulation and development.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MAP2K1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.